Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.
|Number of pages||6|
|Journal||Canadian Journal of Urology|
|State||Published - 2023|
- prostate cancer
- prostate-specific membrane antigen